Coeptis Therapeutics Acquires AI-Powered Marketing Platform, Launches New Tech Division

Coeptis Therapeutics Expands into AI-Powered Marketing

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP), a biopharmaceutical company specializing in cell therapy platforms, has made a significant move into the artificial intelligence sector. The company announced the completion of its acquisition of the NexGenAI Affiliates Network platform and the launch of a new division, Coeptis Technologies 1

1

Strategic Acquisition and New Division

The NexGenAI Affiliates Network platform, developed by NexGenAI Solutions Group, Inc., offers AI-powered marketing software and advanced robotic process automation (RPA) capabilities. This acquisition is aimed at diversifying Coeptis' growth potential and enhancing its capabilities in highly regulated industries such as biotech, pharmaceuticals, and multi-level marketing (MLM) 2

2

AI-Driven Marketing Solutions

The newly acquired platform is designed to empower marketers with tools to:

1. Process vast amounts of data
2. Optimize marketing campaigns
3. Enhance customer engagement
4. Streamline operations

These capabilities are particularly crucial in sectors where regulatory challenges and competition are intense 1

1

Leadership Perspectives

Dave Mehalick, President and CEO of Coeptis Therapeutics, expressed enthusiasm about integrating the AI-driven tools, stating, "In highly competitive industries such as biotech, pharma, and MLM, having advanced tools to optimize marketing, streamline operations, and drive measurable results is not just beneficial -- it's essential for our success." 1

1

Anshuman Dash, Lead Advisory behind the NexGenAI platform development, emphasized the alignment of this acquisition with Coeptis' mission to drive innovation in highly regulated industries 1

1

Related Stories

COEPTIS Launches COEP Venture Group to Invest in AI and Automation Startups

Healthcare AI Market Poised for Explosive Growth as New Technologies Emerge

AI and Healthcare: Roche, Avant Technologies, and Ainnova Partner to Combat Diabetic Retinopathy

AI Revolutionizes Healthcare: Avant Technologies and Roche Partner to Combat Diabetic Retinopathy

Market Impact

The announcement had a significant impact on Coeptis Therapeutics' stock performance. Shares of COEP traded higher by 45.8% to $0.2070 following the news, reflecting positive market sentiment towards the company's strategic move into AI-powered marketing solutions 2

2

Future Implications

This acquisition positions Coeptis to potentially revolutionize marketing strategies and operational efficiencies in the biopharmaceutical sector. By leveraging advanced AI and RPA technologies, the company aims to provide innovative solutions to overcome marketing challenges in biotech, pharma, and MLM industries, setting the stage for future growth and expanded service offerings 2

2